175 related articles for article (PubMed ID: 16210961)
21. [Lymphocele and kidney transplantation].
Langer R; Tóth A; Máthé Z; Remport A; Járay J; Kahan BD
Orv Hetil; 2007 Aug; 148(31):1475-80. PubMed ID: 17656338
[TBL] [Abstract][Full Text] [Related]
22. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
Russ G; Segoloni G; Oberbauer R; Legendre C; Mota A; Eris J; Grinyó JM; Friend P; Lawen J; Hartmann A; Schena FP; Lelong M; Burke JT; Neylan JF;
Transplantation; 2005 Nov; 80(9):1204-11. PubMed ID: 16314787
[TBL] [Abstract][Full Text] [Related]
23. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
[TBL] [Abstract][Full Text] [Related]
24. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
Baboolal K
Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
[TBL] [Abstract][Full Text] [Related]
25. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant.
Hymes LC; Warshaw BL
Pediatr Transplant; 2005 Aug; 9(4):520-2. PubMed ID: 16048606
[TBL] [Abstract][Full Text] [Related]
26. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
Lim WH; Russ GR; Wong G; Pilmore H; Kanellis J; Chadban SJ
Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
[TBL] [Abstract][Full Text] [Related]
27. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
28. Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation.
Gatault P; Bertrand D; Büchler M; Colosio C; Hurault de Ligny B; Weestel PF; Rerolle JP; Thierry A; Sayegh J; Moulin B; Snanoudj R; Rivalan J; Heng AE; Sautenet B; Lebranchu Y
Transpl Int; 2016 Jan; 29(1):41-50. PubMed ID: 26285161
[TBL] [Abstract][Full Text] [Related]
29. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study.
Troppmann C; Pierce JL; Gandhi MM; Gallay BJ; McVicar JP; Perez RV
Transplantation; 2003 Jul; 76(2):426-9. PubMed ID: 12883205
[TBL] [Abstract][Full Text] [Related]
30. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients.
Langer RM; Kahan BD
Transplantation; 2002 Sep; 74(6):804-8. PubMed ID: 12364859
[TBL] [Abstract][Full Text] [Related]
31. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
[TBL] [Abstract][Full Text] [Related]
32. The incidence of cancer and potential role of sirolimus immunosuppression conversion on mortality among a single-center renal transplantation cohort of 1,816 patients.
Branco F; Cavadas V; Osório L; Carvalho F; Martins L; Dias L; Castro-Henriques A; Lima E
Transplant Proc; 2011; 43(1):137-41. PubMed ID: 21335171
[TBL] [Abstract][Full Text] [Related]
33. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
34. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
[TBL] [Abstract][Full Text] [Related]
35. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
[TBL] [Abstract][Full Text] [Related]
36. Preservation of graft function in low-risk living kidney transplant recipients treated with a combination of sirolimus and cyclosporine.
Machado PG; Felipe CR; Park SI; Garcia R; Moreira S; Casarini D; Franco M; Alfieri F; Tedesco-Silva H; Medina-Pestana JO
Braz J Med Biol Res; 2004 Sep; 37(9):1303-12. PubMed ID: 15334195
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study.
Mühlbacher F; Neumayer HH; del Castillo D; Stefoni S; Zygmunt AJ; Budde K;
Transpl Int; 2014 Feb; 27(2):176-86. PubMed ID: 24266855
[TBL] [Abstract][Full Text] [Related]
38. Malignancy after transplantation.
Buell JF; Gross TG; Woodle ES
Transplantation; 2005 Oct; 80(2 Suppl):S254-64. PubMed ID: 16251858
[TBL] [Abstract][Full Text] [Related]
39. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients.
Hakeam HA; Al-Jedai AH; Raza SM; Hamawi K
Ann Transplant; 2008; 13(2):46-53. PubMed ID: 18566560
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
Lehner F; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Witzke O; Wolters HH; Suwelack B; Klehr HU; Stangl M; Hauser IA; Nadalin S; Porstner M; May C; Paulus EM; Sommerer C;
Transpl Int; 2014 Nov; 27(11):1192-204. PubMed ID: 25070687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
